Continuous xRNA Manufacturing Services
A Proven Platform for Accelerated xRNA Manufacturing
Alongside traditional xRNA manufacturing approaches, Recipharm Advanced Bio leverages continuous manufacturing to advance client programs through a proven platform that compresses development timelines, reduces costs, and improves reliability, all while setting a new standard for RNA therapeutics manufacturing.
Powered by our proprietary Recimagine™ Continuous Production System (CPS), our Boston facility applies continuous manufacturing directly within our CDMO services.
The Building Blocks of Accessible xRNA Therapeutics
7-14
Days
to manufacturing mRNA, rather than 3 months
In 2022, average cost of a biological product, $174 per prescription, was 3.7 times greater than average cost of a small molecule drug, $48 per prescription1. While the specific numbers differ slightly in other markets worldwide, the challenge remains: The promise of advanced biologics is inaccessible to many patients due to their expense.
By combining our continually expanding knowledge hub, digital process development, continuous integrated manufacturing, and sophisticated process analytical technologies (PAT), the Recimagine CPS platform sharply decreases timelines. Through continuous and integrated processing and PAT-driven automation, CPS significantly reduces costs and increases accessibility.
Less than 1 month rather than 6-9 months
Recimagine Simulator coupled with high-throughput screening instantly provides process parameters and suggest experimental plans to optimize the recipe.
7-14 days rather than 3 months
The established digital process model informs process analytics controls of the expected results at each stage. Inline analytics monitors progress, ensuring critical quality attributes (CQA) are achieved.
Inline PAT capabilities and predictive analytics monitor processes in real time, eliminating the need for CQA-based gating.
With more and more raw data inputs, the machine learning-enabled Knowledge Hub becomes more intelligent, enabling increasingly robust predictive control and experimental knowledge.
- ASPE Report: Competition in Prescription Drug Markets 2017-2022, December, 2023
The Future of Advanced Therapy Manufacturing Is Fast
By integrating Recimagine CPS into our CDMO operations, we provide the option of a platform that combines extensive scientific expertise, AI-enabled technologies, and state-of-the-art process analytical technologies (PAT) to reduce the finished drug product timeline by up to 67%.
Sequence to final product in less than 4 months
Consolidated xRNA Processing Solutions
Recipharm Advanced Bio provides comprehensive xRNA manufacturing solutions under one roof, including plasmid DNA and lipid nanoparticle (LNP) production.
Our in-house vector design and process development expertise delivers consistently high-quality final pDNA products.
Learn More Recipharm Advanced Bio’s flexible xRNA platform is designed to support a wide range of RNA-based therapeutics, ensuring a reliable, scalable approach from preclinical development through commercial production.
Explore Now Our facilities and equipment are designed for every phase of your project, scale from 1 to 100g, and utilize a range of mixing technologies.
Discover Capabilities Featured Innovations & Collaborations
xRNA Manufacturing Resources
Transform Development and Manufacturing with Recimagine™
The Recimagine ecosystem tackles the toughest challenges in therapeutic production, including high costs, inefficient development, and inconsistent quality. Together, we can reimagine how life-changing therapies are made and deliver them to patients faster than ever before. Partner with us to accelerate what’s next.